Impact of COVID-19 vaccination program on seroprevalence in blood donors in England, 2021

The COVID-19 vaccination programme commenced in England on 8th December 2020 primarily based on age; by 7th March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detec...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitaker, Heather J, Elgohari, Suzanne, Rowe, Cathy, Otter, Ashley David, Brooks, Tim, Linley, Ezra, Hayden, Iain, Ribeiro, Sonia, Hewson, Jacqueline, Lakhani, Anissa, Clarke, Eleanor, Tsang, Camille, Campbell, Colin NJ, Ramsay, Mary, Brown, Kevin, Amirthalingam, Gayatri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of The British Infection Association. 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8110696/
https://www.ncbi.nlm.nih.gov/pubmed/33989631
http://dx.doi.org/10.1016/j.jinf.2021.04.037
Descripción
Sumario:The COVID-19 vaccination programme commenced in England on 8th December 2020 primarily based on age; by 7th March 2021 approximately 93% of the English population aged 70+ years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors.

Ejemplares similares